BioCentury | Jan 5, 2009
Company News

ArQule, Daiichi Sankyo, Roche deal exercise its option under a 2004 deal to license rights to ArQule's cancer compound ARQ 761...
BioCentury | Sep 25, 2008
Distillery Therapeutics

This Week in Therapeutics

This week in therapeutics Indication Target/marker/ pathway Summary Licensing status Publication and contact information Cancer Colorectal cancer E2F transcription factor 1 (E2F1); cyclin-dependent kinase 8 (CDK8); b-catenin Studies in flies and in human cell culture...
BioCentury | Apr 21, 2008
Clinical News

ARQ 761: Phase I start

...This year, ArQule will begin a U.S. Phase I trial of IV ARQ 761. Roche has an...
...program after Phase II testing. ArQule Inc. (NASDAQ:ARQL), Woburn, Mass. Roche (SWX:ROG), Basel, Switzerland Product: ARQ 761...
Items per page:
1 - 3 of 3